ROR1 and hepatocellular carcinoma: In our case, ROR1-knockdown induced chemoresistance in HCC cells against conventional chemotherapeutic agents used in HCC treatment, such as systemically administered Doxorubicin and the platinum derivative, Oxaliplatin, which is used in trans-arterial chemoembolization (TACE) [40,41].